FDA Class II Recall: Amneal Pharmaceuticals' Chlorpromazine Hydrochloride Packaging Contamination Prompts Supply Chain Review
Amneal Pharmaceuticals, LLC has initiated a Class II recall for 3,363 bottles of Chlorpromazine Hydrochloride Tablets, USP, 200 mg, due to microbial contamination in packaging materials. This event, originating from its Ahmedabad, India manufacturing site, necessitates immediate supply chain assessment for procurement and regulatory teams, highlighting critical vulnerabilities in packaging material quality control and global pharmaceutical distribution networks.
FDA Class II Recall: Amneal's Chlorpromazine Hydrochloride Packaging Contamination
Amneal Pharmaceuticals, LLC has initiated a Class II voluntary recall, identified as D-0619-2025, for specific lots of its CHLORPROMAZINE HYDROCHLORIDE Tablets, USP, 200 mg. This action, initiated on August 18, 2025, stems from the detection of a micro-organism within a specific lot of auxiliary polyester coil used in the product's packaging. Crucially, the FDA's findings confirm that no micro-organisms were detected on the tablets themselves, indicating the contamination was confined to the packaging component. The recall affects 3,363 100-count bottles distributed nationwide across the USA, impacting product NDCs including 69238-1062-1. For procurement directors, this means an immediate disruption to the supply of Amneal's Chlorpromazine Hydrochloride, specifically lots AM240336 and AM240337 with an expiration date of February 28, 2027. Supply chain VPs must promptly assess current inventory levels and identify alternative sourcing strategies to ensure continuity for this critical antipsychotic medication, even though the Class II classification suggests a remote probability of serious adverse health consequences.
Global Supply Chain Vulnerabilities: Manufacturing in India, Distribution in the US
The recalled CHLORPROMAZINE HYDROCHLORIDE Tablets, USP, 200 mg, were manufactured by Amneal Pharmaceuticals Pvt. Ltd. in Ahmedabad 382213, India, and subsequently distributed by Amneal Pharmaceuticals LLC from Bridgewater, NJ 08807, United States. This geographical split highlights the inherent complexities and potential vulnerabilities within global pharmaceutical supply chains. The incident underscores that quality control extends beyond active pharmaceutical ingredients (APIs) and finished product testing to encompass all ancillary materials, including packaging components sourced from diverse international suppliers. For regulatory affairs heads, this event emphasizes the need for robust oversight of contract manufacturing organizations (CMOs) and packaging material suppliers, particularly those operating in different regulatory jurisdictions. Business development executives considering global expansion or outsourcing models must factor in the heightened scrutiny on end-to-end supply chain integrity, from raw material sourcing to final distribution, to mitigate similar recall risks and maintain market access for products like Chlorpromazine Hydrochloride (ANDA209755).
Market Impact and Product Availability for Chlorpromazine Hydrochloride
The recall of Amneal Pharmaceuticals' CHLORPROMAZINE HYDROCHLORIDE Tablets, USP, 200 mg, directly impacts the availability of this essential medication across the United States. With 3,363 100-count bottles affected, purchasers who rely on Amneal for this product will experience immediate supply constraints. Chlorpromazine Hydrochloride is a critical antipsychotic, and any disruption, even if the contamination is limited to packaging, can pose challenges for healthcare providers and patients. Procurement directors must urgently review their purchasing agreements and inventory of Amneal's Chlorpromazine Hydrochloride (product NDCs 69238-1054, 69238-1056, 69238-1058, 69238-1060, 69238-1062) to determine their exposure. Supply chain VPs should activate contingency plans, exploring alternative suppliers or different strengths/formulations of chlorpromazine, if available, to prevent stockouts. Regulatory affairs heads must communicate effectively with healthcare providers and potentially the FDA regarding supply status and mitigation efforts, ensuring patient access is maintained despite this quality incident.
Amneal's Immediate Remediation and Future Regulatory Scrutiny
As a firm-initiated, voluntary Class II recall, Amneal Pharmaceuticals, LLC is now responsible for implementing comprehensive corrective and preventive actions (CAPA) to address the root cause of the micro-organism detection in its packaging material. The recall status is ongoing, with the initial firm notification occurring via letter, and the FDA's center classification date on September 4, 2025. This requires Amneal to meticulously investigate its packaging material supply chain, specifically the auxiliary polyester coil, and enhance quality control measures at its manufacturing facility in Ahmedabad, India. For regulatory affairs heads, this incident signals potential for increased FDA scrutiny on Amneal's manufacturing and quality systems, particularly concerning non-drug contact materials. Procurement directors should closely monitor Amneal's remediation progress, as the effectiveness of these actions will dictate future supply reliability for Chlorpromazine Hydrochloride and other products. A failure to adequately address the issue could lead to further regulatory actions, including potential import alerts or more severe classifications, impacting Amneal's broader product portfolio and market standing.
Broader Industry Implications: Sterility and Packaging Material Sourcing
The Amneal Pharmaceuticals recall of CHLORPROMAZINE HYDROCHLORIDE due to packaging contamination underscores a broader industry challenge in maintaining sterility and quality across all components of pharmaceutical products. This event aligns with recent regulatory actions, such as the FDA's Class II recall of Essential Wellness Pharma's Progesterone Injection in June 2026, which also cited failures in sterility assurance. For procurement directors, these incidents highlight the imperative of extending rigorous supplier qualification and audit programs beyond API and excipient suppliers to include all packaging material vendors. The presence of micro-organisms, even in auxiliary packaging not directly contacting the drug, signals a potential breach in environmental controls or material handling that could escalate. Supply chain VPs must implement robust incoming material inspection protocols and consider the microbiological testing of packaging components. Regulatory affairs heads should anticipate increased FDA focus on comprehensive quality management systems that encompass all aspects of the supply chain, pushing for greater transparency and control over third-party material suppliers to prevent similar disruptions for critical human prescription drugs.